Table 2.
Clinical characteristics and outcomes of ICI colitis (n=16)
| Characteristics | Frequency (%) or Median (IQRs) |
|---|---|
| Time from first ICI infusion to colitis (month) | 3.0 (1.0-9.0) |
| PPI Exposure | 14 (87.5%) |
| PPI Exposure Duration (month) | 19.5 (5.3-31.8) |
| Colitis grade | |
| II | 9 (56.3) |
| III | 7 (43.8) |
| Number of bowel movements per day | 5 (3-8) |
| Symptoms duration (day) | 8.5 (5.0 - 14.0) |
| Stool lactoferritin positive (n=15) | 15 (100) |
| Stool calprotectin elevated (n=14) | 14 (100) |
| Endoscopy | 10 (62.5) |
| Time from symptom onset to endoscopy (day) | 8 (4-24) |
| Endoscopic findings (n=10) | |
| Normal | 5 (50) |
| Focal inflammation | 2 (20) |
| Diffuse inflammation | 3 (30) |
| Histologic findings (n=10)a | |
| Normal | 1 (10) |
| Acute inflammation | 9 (90) |
| Chronic inflammation | 3 (30) |
| Lymphocytic pattern | 6 (60) |
| Treatment | |
| ICI suspended | 16 (100) |
| Steroids | 16 (100) |
| Infliximab | 3 (18.8) |
| Outcomes | |
| Hospitalization | 7 (43.8) |
| ICI resumed | 6 (37.5) |
| Time to resumption (week) | 10 (7.5-14.5) |
| Recurrence | 5 (83.3) |
| Concurrent irAEsb | |
| Any | 10 (62.5) |
| Polyarthralgia | 3 (18.8) |
| Pneumonitis | 2 (12.5) |
| Dermatitis | 2 (12.5) |
| Hepatitis | 2 (12.5) |
| Pancreatitis | 2 (12.5) |
| Otherc | 3 (18.8) |
Data are shown as frequencies (percentages) or medians (interquartile ranges).
a
Some patients had multiple histological findings.
b
Some patients had multiple irAEs.
c
Other includes development of Type 1 diabetes and adrenal insufficiency in a single patient, hypophysitis (n = 1), and iritis (n = 1).
ICI: immune-checkpoint inhibitor, irAE: immune-related adverse event, PPI: proton pump inhibitor.